DBK Pharmaceutical:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:DBK Pharmaceutical - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10529
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:エジプト
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
DBK Pharmaceutical (DBK Pharma) is a pharmaceutical company that develops, manufactures and markets pharmaceutical, herbal brands, food supplements, cosmetics and veterinary products. The company’s pharmaceutical products include chitocal capsule, debeskon, rentensar tablets, pressothioval, lidocaine with adrenaline, malsa cream, depahair, lycomen, debosteobone tablets, dermaflutisone cream, bold stop, and others. Its cosmetics products comprise skincare and personal care products. DBK Pharma offers veterinary products such as gentamycin, gamamox, ronoxy, solpharon, debatoltra, enterobiotic, dectomectin, painclear and dimetro. The company retails products through a network of distributors in Middle East and African countries. DBK Pharma is headquartered in Cairo, Egypt.

DBK Pharmaceutical – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
DBK Pharmaceutical, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
DBK Pharmaceutical, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
DBK Pharmaceutical, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
DBK Pharmaceutical, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
DBK Pharmaceutical, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
DBK Pharmaceutical, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
Marei Bin Mahfouz Acquires 25% Stake in DBK Pharma for USD2.2 Million 10
Equity Offering 11
DBK Pharma to Raise USD15.8 Million in Private Placement of Shares 11
DBK Pharma Postpones Initial Public Offering 12
DBK Pharmaceutical – Key Competitors 13
DBK Pharmaceutical – Key Employees 14
DBK Pharmaceutical – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
DBK Pharmaceutical, Pharmaceuticals & Healthcare, Key Facts 2
DBK Pharmaceutical, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
DBK Pharmaceutical, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
DBK Pharmaceutical, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
DBK Pharmaceutical, Deals By Therapy Area, 2012 to YTD 2018 8
DBK Pharmaceutical, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Marei Bin Mahfouz Acquires 25% Stake in DBK Pharma for USD2.2 Million 10
DBK Pharma to Raise USD15.8 Million in Private Placement of Shares 11
DBK Pharma Postpones Initial Public Offering 12
DBK Pharmaceutical, Key Competitors 13
DBK Pharmaceutical, Key Employees 14

List of Figures
DBK Pharmaceutical, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
DBK Pharmaceutical, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
DBK Pharmaceutical, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
DBK Pharmaceutical, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
DBK Pharmaceutical, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
DBK Pharmaceutical, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
DBK Pharmaceutical, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
DBK Pharmaceutical, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[DBK Pharmaceutical:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Sherwin-Williams Company:企業の戦略・SWOT・財務分析
    The Sherwin-Williams Company - Strategy, SWOT and Corporate Finance Report Summary The Sherwin-Williams Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Huawei Technologies Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Huawei Technologies Co., Ltd. (Huawei), a subsidiary of Huawei Investment & Holding Co., Ltd, is an information and communication technology company. The company’s product portfolio includes mobile, broadband, core network, transmission network, and data communication products, besides value …
  • EL Sewedy Electric Co (SWDY):企業の財務・戦略的SWOT分析
    EL Sewedy Electric Co (SWDY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Exillon Energy Plc (EXI):石油・ガス:M&Aディール及び事業提携情報
    Summary Exillon Energy Plc (Exillon) is an oil exploration and production company. The company explores, produces and develops crude oil. Its services include drilling, exploration, appraisal, development, operations, management, and production services. Exillon’s operating assets are located in two …
  • Wartsila Corporation (WRT1V):電力:M&Aディール及び事業提携情報
    Summary Wartsila Corporation (Wartsila) is a mechanical or industrial engineering company. It offers smart technologies and complete lifecycle solutions. Through sustainable innovation, total efficiency, and data analytics, the company harnesses the environmental and economic performance of the vess …
  • Shima Seiki Mfg Ltd (6222):企業の財務・戦略的SWOT分析
    Shima Seiki Mfg Ltd (6222) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Advanced Ground Systems Engineering LLC:企業の戦略・SWOT・財務情報
    Advanced Ground Systems Engineering LLC - Strategy, SWOT and Corporate Finance Report Summary Advanced Ground Systems Engineering LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Anagenesis Biotechnologies:製薬・医療:M&Aディール及び事業提携情報
    Summary Anagenesis Biotechnologies is a pharmaceutical solutions provider that offers treatment for muscle degenerative diseases. The company provides cell therapy genetics and pharmacological drugs for genetic and age related diseases. It also carries out cell-based technologies to provide solution …
  • Xped Ltd (XPE):企業の財務・戦略的SWOT分析
    Xped Ltd (XPE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Wacker Chemie AG (WCH)-エネルギー分野:企業M&A・提携分析
    Summary Wacker Chemie AG (Wacker) develops, manufactures, and markets various chemical and semiconductor materials. It offers a range of silicone fluids and emulsions, resins, elastomers, sealants and silanes. The company manufactures binders and polymeric additives such as dispersible polymer powde …
  • Boralex Inc (BLX):企業の財務・戦略的SWOT分析
    Boralex Inc (BLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Kinder Morgan Inc (KMI):企業の財務・戦略的SWOT分析
    Kinder Morgan Inc (KMI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Hays plc:企業の戦略・SWOT・財務情報
    Hays plc - Strategy, SWOT and Corporate Finance Report Summary Hays plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • SunOpta Inc.:企業のM&A・事業提携・投資動向
    SunOpta Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SunOpta Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Mitsubishi Heavy Industries, Ltd.:戦略・SWOT・企業財務分析
    Mitsubishi Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Xtant Medical Holdings Inc (XTNT)-製薬・医療分野:企業M&A・提携分析
    Summary Xtant Medical Holdings Inc (Xtant Medical), formerly Bacterin International Holdings, Inc. is a medical device company that develops regenerative medicine products and medical devices. The company’s products include 3Demin, osteosponge, osteosponge SC, osteoselect DBM Putty, OsteoSTX, osteow …
  • New China Life Insurance Company Ltd.:企業の戦略・SWOT・財務分析
    New China Life Insurance Company Ltd. - Strategy, SWOT and Corporate Finance Report Summary New China Life Insurance Company Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Zealand Pharma AS (ZEAL):製薬・医療:M&Aディール及び事業提携情報
    Summary Zealand Pharma AS (Zealand) is a biotechnology company that discovers, designs and develops peptide based medicines that targets specialty diseases. The company’s marketed products comprise Lyxumia and Suliqua for the treatment of Type 2 diabetes and others for the treatment of obesity and f …
  • Oman Telecommunications Company SAOG:企業の戦略・SWOT・財務情報
    Oman Telecommunications Company SAOG - Strategy, SWOT and Corporate Finance Report Summary Oman Telecommunications Company SAOG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Enteris BioPharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Enteris BioPharma Inc (Enteris) is a biotechnology company that offers formulation solutions based on proprietary drug delivery technologies. The company’s product candidate includes oral leuprolide tablet, which is developed for endometriosis in women. Its other product candidates comprise …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆